# Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

> **NCT02464228** · PHASE2 · COMPLETED · sponsor: **Kura Oncology, Inc.** · enrollment: 65 (actual)

## Conditions studied

- Relapsed or Refractory Peripheral T-Cell Lymphoma

## Interventions

- **DRUG:** Tipifarnib

## Key facts

- **NCT ID:** NCT02464228
- **Lead sponsor:** Kura Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-25
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464228, "Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02464228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*